For shame: ‘Phar­ma Bro’ Shkre­li is in prison, but Dara­prim’s price is still high

It was 2015 when Mar­tin Shkre­li, then CEO of Tur­ing Phar­ma­ceu­ti­cals and the no­to­ri­ous “phar­ma bro,” jacked up the cost of the life­sav­ing drug Dara­prim by 5,000 per­cent. Overnight, its price tag sky­rock­et­ed from $13.50 a pill to $750.

The move drew crit­i­cism from all cor­ners. Con­gress hauled Shkre­li in for ques­tion­ing on tele­vi­sion. Me­dia out­lets shamed the prac­tice. The Phar­ma­ceu­ti­cal Re­search and Man­u­fac­tur­ers of Amer­i­ca (PhRMA), the pow­er­ful trade group for brand­ed drugs, dis­tanced it­self, say­ing Tur­ing “does not rep­re­sent the val­ues of@PhRMA” and kicked off a cam­paign it de­scribed as “more lab coat, less hood­ie.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.